现代肿瘤医学
現代腫瘤醫學
현대종류의학
JOURNAL OF MODERN ONCOLOGY
2014年
9期
2032-2035
,共4页
梁玲霞%田晓予%王瑞芳%王盈%王建刚%席守民
樑玲霞%田曉予%王瑞芳%王盈%王建剛%席守民
량령하%전효여%왕서방%왕영%왕건강%석수민
索拉非尼%宫颈癌%Hela细胞%VEGFR-3%PDGFR-β
索拉非尼%宮頸癌%Hela細胞%VEGFR-3%PDGFR-β
색랍비니%궁경암%Hela세포%VEGFR-3%PDGFR-β
sorafenib%cervical cancer%Hela cells%VEGFR-3%PDGFR-β
目的:研究索拉非尼能否抑制宫颈癌Hela细胞增殖、抑制Hela细胞中VEGFR-3和PDGFR-β的表达。方法:四甲基偶氮唑蓝(MTT)快速比色法检测索拉非尼作用于Hela细胞24h、48h、72h后细胞增殖率, Hoechst荧光染色观察药物作用(1mg/L)48h后的凋亡细胞,细胞免疫荧光法和Western blot检测不同浓度的索拉非尼(1mg/L、0.1mg/L、0.01mg/L)作用Hela细胞VEGFR-3和PDGFR-β表达情况。结果:不同浓度的索拉非尼作用Hela细胞后,Hela 细胞的增殖率下降,呈浓度依赖性(P<0.05),随着药物浓度的增加Hela细胞的增殖率不断下降。药物作用后能观察到凋亡的Hela细胞,细胞核变小、固缩,荧光明显增强。正常Hela细胞中有VEGFR-3和PDGFR-β表达,索拉非尼作用后,Hela细胞绿色荧光明显减弱,VEGFR-3和PDGFR-β表达明显降低,呈浓度依赖性。结论:索拉非尼能够诱导Hela细胞的凋亡,抑制其增殖且呈浓度依赖性。索拉非尼能够抑制Hela细胞VEGFR-3和PDGFR-β表达,可能降低Hela细胞侵袭转移的能力。
目的:研究索拉非尼能否抑製宮頸癌Hela細胞增殖、抑製Hela細胞中VEGFR-3和PDGFR-β的錶達。方法:四甲基偶氮唑藍(MTT)快速比色法檢測索拉非尼作用于Hela細胞24h、48h、72h後細胞增殖率, Hoechst熒光染色觀察藥物作用(1mg/L)48h後的凋亡細胞,細胞免疫熒光法和Western blot檢測不同濃度的索拉非尼(1mg/L、0.1mg/L、0.01mg/L)作用Hela細胞VEGFR-3和PDGFR-β錶達情況。結果:不同濃度的索拉非尼作用Hela細胞後,Hela 細胞的增殖率下降,呈濃度依賴性(P<0.05),隨著藥物濃度的增加Hela細胞的增殖率不斷下降。藥物作用後能觀察到凋亡的Hela細胞,細胞覈變小、固縮,熒光明顯增彊。正常Hela細胞中有VEGFR-3和PDGFR-β錶達,索拉非尼作用後,Hela細胞綠色熒光明顯減弱,VEGFR-3和PDGFR-β錶達明顯降低,呈濃度依賴性。結論:索拉非尼能夠誘導Hela細胞的凋亡,抑製其增殖且呈濃度依賴性。索拉非尼能夠抑製Hela細胞VEGFR-3和PDGFR-β錶達,可能降低Hela細胞侵襲轉移的能力。
목적:연구색랍비니능부억제궁경암Hela세포증식、억제Hela세포중VEGFR-3화PDGFR-β적표체。방법:사갑기우담서람(MTT)쾌속비색법검측색랍비니작용우Hela세포24h、48h、72h후세포증식솔, Hoechst형광염색관찰약물작용(1mg/L)48h후적조망세포,세포면역형광법화Western blot검측불동농도적색랍비니(1mg/L、0.1mg/L、0.01mg/L)작용Hela세포VEGFR-3화PDGFR-β표체정황。결과:불동농도적색랍비니작용Hela세포후,Hela 세포적증식솔하강,정농도의뢰성(P<0.05),수착약물농도적증가Hela세포적증식솔불단하강。약물작용후능관찰도조망적Hela세포,세포핵변소、고축,형광명현증강。정상Hela세포중유VEGFR-3화PDGFR-β표체,색랍비니작용후,Hela세포록색형광명현감약,VEGFR-3화PDGFR-β표체명현강저,정농도의뢰성。결론:색랍비니능구유도Hela세포적조망,억제기증식차정농도의뢰성。색랍비니능구억제Hela세포VEGFR-3화PDGFR-β표체,가능강저Hela세포침습전이적능력。
Objective:To investigate whether sorafenib can inhabit the proliferation of Hela cells and inhibit the expression of VEGFR-3 and PDGFR-βin Hela cells.Methods:MTT assay was used to analyze cells proliferation rate after treatment with different concentration of sorafenib for 24h,48h,72h.Hoechst 33258 was used to stain nucle-us of Hela cells treatment with sorafenib (1.0mg/L),48h later,observed nucleus morphological changes.Immunoflu-orescence and Western blot was used to observe the expression of VEGFR-3 and PDGFR-βin Hela cells with the treatment of different concentration of sorafenib (1mg/L,0.1mg/L,0.01mg/L).Results:After treatment with differ-ent concentration of sorafenib ,the proliferation rate of Hela cells was down ,and it has dose-dependent effect (P<0.05).Sorafenib can make Hela cells apoptosis.The apoptotic cells,nuclear small,pyknosis,fluorescence enhanced obviously.We can observe the expression of VEGFR-3 and PDGFR-βin Hela cells.The green fluorescence was re-duced with the treatment of sorafenib,the expression of VEGFR-3 and PDGFR-βin Hela cells were down,and it had dose -dependent effect.Conclusion:Sorafenib can make Hela cells apoptosis,inhibit the proliferation of Hela cells and it has dose-dependent effect.Sorafenib can inhibit the expression of VEGFR-3 and PDGFR-βin Hela cells,maybe sorafenib can decrease the property of its invasion and metastasis.